Evidence map›Paper›PMID 38656623›Full record

ArticleJournal of neurology2024

Rituximab in non-systemic vasculitic neuropathy: a single-center experience.

Felix Kohle, Gilbert Wunderlich, Gereon R Fink, Michael Schroeter, Helmar C Lehmann, Christian Schneider

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Felix KohleDepartment of Neurology, Faculty of Medicine, University of Cologne and University Hospital Cologne, Cologne, Germany. felix.kohle@uk-koeln.de.ORCID http://orcid.org/0000-0002-4429-0367
Gilbert WunderlichDepartment of Neurology, Faculty of Medicine, University of Cologne and University Hospital Cologne, Cologne, Germany.
Gereon R FinkDepartment of Neurology, Faculty of Medicine, University of Cologne and University Hospital Cologne, Cologne, Germany.
Michael SchroeterDepartment of Neurology, Faculty of Medicine, University of Cologne and University Hospital Cologne, Cologne, Germany.
Helmar C LehmannDepartment of Neurology, Hospital Leverkusen, Leverkusen, Germany.
Christian SchneiderDepartment of Neurology, St. Katharinen Hospital, Frechen, Germany.
University of Cologne · DEForschungszentrum Jülich · DEKatharinenhospital · DEKlinikum Leverkusen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis case series reports clinical features and outcome of four patients with non-systemic vasculitic neuropathy (NSVN) treated with the anti-CD20 agent rituximab.

methodsClinical, electrophysiological and biopsy data were retrospectively obtained and evaluated. Only patients with pathological definite or probable NSVN were included. Extensive clinical and laboratory work-up excluded systemic vasculitis. Follow-up data for at least 12 months and up to five years is provided. Outcome of the patients was assessed using the MRC-Sum Score, Prineas Score and Neurological Symptom Score.

resultsTwo of four patients treated with rituximab achieved disease remission and one patient remained stable under anti-CD20 therapy after a required treatment switch due to toxic side effects of cyclophosphamide. One patient deteriorated under rituximab induction. Rituximab was well tolerated in all patients. DISCUSSION: Anti-CD20 therapy might be an alternative in NSVN patients requiring further treatment escalation or treatment switch due to side effects of corticosteroids or cyclophosphamide.

Indexed as

Immunologic FactorsPeripheral Nervous System DiseasesRituximabVasculitisAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesImmunologic FactorsRituximabAntibodiesb-lymphocytesDrug repurposingPeripheral nervous systemPolyneuropathiesVasculitis

Identifiers

PMID38656623
PMCPMC11233319
OpenAlexW4395072988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.